Friday's Biotech/Pharma Stocks Trading

Point Roberts, WA - August 15, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks reports on trading and recent news for companies providing novel approaches to cancer therapy . In a roller coaster market of trading last week, several of the biotech/pharma stocks closed on the upside on Friday. Analyst Jeffrey Holford of A Jefferies & Co told clients on Friday, "We believe that the sector (pharmaceuticals stocks ) will soon likely act as a safe haven once investors reposition portfolios for slower growth and increased uncertainty over government and corporate balance sheets. " Aethlon Medical AEMD traded in a range of $0.0750 - 0.0780 on Friday . The Company released a new investor slide show/ media player entitled A Novel Therapeutic Strategy to Address Cancer. According to the presentation , “The Aethlon Hemopurifier® is the first therapeutic candidate to eliminate cancer exosomes from circulation ,providing a therapeutic filtration mechanism to remove cancer exosomes from the circulatory system. It allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces, and provides access to the entire circulatory system. Exosomes can be accessed from entire circulatory system, which can pass through the Hemopurifier® in as little as 15 minutes. The Hemopurifier® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are already located in hospitals in clinics. Bristol-Myers Squibb Company BMY closed at $27.97, up 0.17 (0.61%) in Friday's trading . According to the company's Second Quarter report July 28 th , there are several key developments in its oncology divisions. In June, the Company entered into a clinical collaboration agreement with Roche to conduct a Phase I/II study to evaluate the safety and efficacy of the combination of YERVOY and vemurafenib in treating patients with metastatic melanoma. In July, the Company announced a global agreement with Innate Pharma S.A., a biotech company in France, for the development and commercialization of IPH 2102, a novel immuno-oncology biologic in Phase I development. Dendreon Corporation DNDN closed Friday at $10.44, up 0.07 (0.68%) on over 8 million shares. The Company reported Second Quarter results August 3 rd and noted, "Our accomplishments this year are foundational as we introduce an entirely new treatment paradigm for patients with advanced prostate cancer," continued Dr. Gold. "These position us well to realize the significant market potential of PROVENGE, and we have identified a solid and clear path to ensuring that the many men who can benefit from it have access to our life-extending drug." GlaxoSmithKline GSK ended trading on Friday at $41.30, up 0.49 (1.20%). Biotech/Pharma Company Snapshot for Aethlon Medical AEMD Visit the showcase page on Investorideas.com http://www.investorideas.com/CO/AEMD Get added to the company's news alerts: http://www.investorideas.com/Resources/Newsletter.asp OTCBB:AEMD slide show / media - A Novel Therapeutic Strategy to Address Cancer http://www.slideshare.net/Aethlon/a-novel-therapeutic-strategy-to-address-cancer A Novel Therapeutic Strategy to Address Cancer - Presentation Transcript 1.A Novel Therapeutic Strategy to Address Cancer September 2011 2.Cancer is the leading cause of deathworldwide and accounted for 7.6 million deaths in 2008 alone 3.There were 12.7 million new cases of Cancer in 2008 4.Cancer deaths in the United States are expected to exceed 570,000 in 2011 5.In 2011, new cases of Cancer are expected to exceed 1,500,000 in the U.S. 6.Innovative strategies are needed to address Cancer progression mechanisms that are beyond the reach of current drug therapies 7.A therapeutic strategy that could inhibit the proliferation of immunosuppressive exosomes released by solid tumors, lymphomas and leukemias would fill a significant unmet medical need in cancer care 8.What are Exosomes?• Cancer cells, both in vivo and in vitro, have been demonstrated to release membranous structures, defined as exosomes 9.Researchers have recently unveiled several roles that exosomes play in accelerating cancer progression 10.The resulting research publications are reporting that................ 11.Exosomes cause apoptosis or programmed cell death of immune cells 12.Exosomes disrupt signaling of anti-cancer T cells 13.Exosomes contribute to tumor angiogenesis 14.Exosomes enhance the spread of tumor metastasis 15.The quantity of exosomes in circulation is indirect correlation with cancer progression 16.What if exosomes could be eliminated from circulation? 17.The Aethlon Hemopurifier® The first therapeutic candidate to eliminate cancer exosomes from circulation 18.The Aethlon Hemopurifier®• Provides a therapeutic filtration mechanism to remove cancer exosomes from the circulatory system• Allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces 19.Providing access to the entire circulatory system• Exosomes can be accessed from entire circulatory system, which can pass through the Hemopurifier® in as little as 15 minutes 20.Hemopurifier® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are already located in hospitals in clinics 21.Our goal is to improve patient responsiveness to traditional chemotherapies and emerging classes of immune based therapies 22.To improve patient responsiveness without additional drug toxicity or interaction risks 23.In vitro binding of exosomes underlying the following cancers has been demonstrated• Breast• Ovarian• Colorectal• Lymphoma• Melanoma 24.Human Hemopurifier® treatment experience already exists 25.The Hemopurifier® has previously demonstrated the ability to reduce viral load in HIV and hepatitis C (HCV) infected individuals without the administration of antiviral drugs 26.A clinical study to evaluate the ability of the Hemopurifier® to improve HCV drug therapy benefit is currently being conducted 27.The clinical application of the Hemopurifier® in Cancer? 28.We are currently collaborating with candidate investigators to develop a clinical protocol to demonstrate the ability of our Hemopurifier® to eliminate circulating cancer exosomes 29.We invite you to follow our efforts to improve cancer care AethlonMedical.com 30.Our mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions Thank You 31.ContactJim Joyce Chairman, CEO8910 University Center Lane San Diego , California92122jj@aethlonmedical.com This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements be subject to the safe harbor created thereby. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including the company's ability to successfully obtain FDA and other regulatory approvals for the sale of its products, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, and the company's ability to raise capital when needed. Some information in this presentation, or on which this presentation is based, has been obtained from sources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties. Such risks and uncertainties, including those discussed above, are more fully described in the Securities and Exchange Commission (SEC) reports filed by Aethlon Medical, Inc., including its most recent annual report on Form 10-K. This presentation speaks only as of its date, and the company disclaims any duty to update the information herein. Further information is avail able by contacting the company or at the company's website at www.aethlonmedical.com. Contacts: James A. Joyce Chairman, CEO 858.459.7800 x301 jj@aethlonmedical.com About InvestorIdeas.com: InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming. Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, 200,000 144 shares ) OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 800-665-0411 - cvanzant@investorideas.com Source - Investorideas.com